Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 556 AL 570

Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials

Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, Sparks J, Andersen S, Lauzon S, Nery ESM, Battioui C, Engle SE, Biffi A, Svaldi D, Salloway S, Greenberg SM, Sperling RA, Mintun M, Brooks DA, Sims JR.

JAMA Neurol. 2025 May 1;82(5):461-469. doi: 10.1001/jamaneurol.2025.0065.

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease

Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, León T, Scheltens P.

Alzheimers Res Ther. 2025 Jan 8;17(1):14. doi: 10.1186/s13195-024-01666-7.

Regional disparities of antidementia drug treatment in Germany: what can we learn for the new generation of Alzheimer's therapies

Platen M, Gläser E, Dahling V, Gesell D, Hauptmann M, Horenkamp-Sonntag D, Koller D, Kubat D, Marschall U, Riederer C, Scheibner H, Schroth J, Swart E, Michalowsky B.

Alzheimers Res Ther. 2025 Dec 4;17(1):259. doi: 10.1186/s13195-025-01902-8.

Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?

Davidson M, Stanciu GD, Rabinowitz J, Untu I, Dobrin RP, Tamba BI.

Dialogues Clin Neurosci. 2025 Dec;27(1):1-12. doi: 10.1080/19585969.2025.2480566. Epub 2025 Mar 19.

Association between duration, initiation time, routes, and formulations of menopausal hormone therapy use and Alzheimer disease in women: A systematic review and meta-analysis

Song Q, Wang Q, Wu D, Zhang Z, Chen M, Fu C, Li M, Wang X, Zhao Y, Zhu D.

J Pharmacol Exp Ther. 2025 May;392(5):103554. doi: 10.1016/j.jpet.2025.103554. Epub 2025 Mar 19.

Seizing the link: Exploring the potential association between anti-seizure medications and Alzheimer's disease

Zawar I, Kapur J.

J Alzheimers Dis. 2025 Aug;106(3):917-919. doi: 10.1177/13872877251350291. Epub 2025 Jun 16.

Association of antihypertensive drug target genes with alzheimer's disease: a mendelian randomization study

Zheng H, Chen C, Feng Y.

Alzheimers Res Ther. 2025 Jan 10;17(1):18. doi: 10.1186/s13195-025-01671-4.

Multi-ancestry genome-wide meta-analysis of 56,241 individuals identifies known and novel cross-population and ancestry-specific associations as novel risk loci for Alzheimer's disease

Rajabli F, Benchek P, Tosto G, Kushch N, Sha J, Bazemore K, Zhu C, Lee WP, Haut J, Hamilton-Nelson KL, Wheeler NR, Zhao Y, Farrell JJ, Grunin MA, Leung YY, Kuksa PP, Li D, da Fonseca EL, Mez JB, Palmer EL, Pillai J, Sherva RM, Song YE, Zhang X, Ikeuchi T, Iqbal T, Pathak O, Valladares O, Reyes-Dumeyer D, Kuzma AB, Abner E, Adams LD, Adams PM, Aguirre A, Albert MS, Albin RL, Allen M, Alvarez L, Apostolova LG, Arnold SE, Asthana S, Atwood CS, Auerbach S, Ayres G, Baldwin CT, Barber RC, Barnes LL, Barral S, Beach TG, Becker JT, Beecham GW, Beekly D, Benitez BA, Bennett D, Bertelson J, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Brewer J, Burke JR, Burns JM, Buxbaum JD, Cairns NJ, Cantwell LB, Cao C, Carlson CS, Carlsson CM, Carney RM, Carrasquillo MM, Chasse S, Chesselet MF, Chin NA, Chui HC, Chung J, Craft S, Crane PK, Cribbs DH, Crocco EA, Cruchaga C, Cuccaro ML, Cullum M, Darby E, Davis B, De Jager PL, DeCarli C, DeToledo J, Dick M, Dickson DW, Dombroski BA, Doody RS, Duara R, Ertekin-Taner N, Evans DA, Faber KM, Fairchild TJ, Fallon KB, Fardo DW, Farlow MR, et al.

Genome Biol. 2025 Jul 17;26(1):210. doi: 10.1186/s13059-025-03564-z.

Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes

Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, Chen WM, Wu SY, Zhang J.

Diabetes Metab. 2025 Mar;51(2):101623. doi: 10.1016/j.diabet.2025.101623. Epub 2025 Feb 12.

New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions

Mosconi L, Nerattini M, Williams S, Fink M.

J Clin Endocrinol Metab. 2025 Mar 17;110(4):911-921. doi: 10.1210/clinem/dgaf026.

ADNI Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion (DE&I) Working Group: A new collaboration that crosses boundaries for industry, academia, and under-represented patients

Croney R, Fristed E, Masterman D, Meyer M, Sachdev P, Vasanthakumar A, Weber CJ, Devins T.

Alzheimers Dement. 2025 Jan;21(1):e14248. doi: 10.1002/alz.14248. Epub 2024 Dec 22.

Conventional and Emerging Drug Targeting Sites in Alzheimer's Disease and the Role of Translational Informatics in its Diagnosis and Management

Khan KA, Esa M, Kamal Z, Ullah B, Perry G, Kamal S, Ahmad S, Hussain H, Ullah A, Shafique M.

Curr Neuropharmacol. 2025;23(14):1894-1917. doi: 10.2174/011570159X361867250313073624.

The importance of non-pharmacological interventions to improve cognitive reserve prior to the administration of a drug against the causative agent of Alzheimer's disease

Maki Y, Ubuka T, Yamane Y.

J Alzheimers Dis. 2025 Jan;103(2):358-360. doi: 10.1177/13872877241301806. Epub 2024 Dec 5.

Recent Advances in the Application of Artificial Intelligence in Alzheimer's Disease

Yao L, Ni J, Wei M, Li T, Li F, Wang T, Xiao W, Shi J, Tian J.

Curr Alzheimer Res. 2025;22(11):815-827. doi: 10.2174/0115672050410489250930175402.

PDE4D inhibitors: Opening a new era of PET diagnostics for Alzheimer's disease

Shi L, Wang X, Si H, Song W.

Neurochem Int. 2025 Jan;182:105903. doi: 10.1016/j.neuint.2024.105903. Epub 2024 Dec 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias